"Bang!"
After hanging up the phone, Hoffman slammed the table forcefully, his eyes filled with rage.
As a PFE researcher, Richard saw the negative impact on himself, and the company that had invested a massive amount of research funds.
But as an editor-in-chief, what Hoffman saw was the enormous negative impact on the entire industry.
Ever since that "classic among classics" validated oligomer Aβ56, the related medical industry had started to bet heavily on it.
Just last year alone, the support from Oceanic Health Research Institute (NIH) for "amyloid-beta, oligomers, and Alzheimer's disease" reached a staggering one billion US dollars.
This amount nearly accounted for half of the NIH's total funding for Alzheimer's research!
If this scope was expanded to the whole world, and the timeline extended, then the research funds derived from this paper over the past sixteen years amounted to an astronomical figure of several hundred billion US dollars!
